Novo Nordisk

Novo Nordisk in Fortune Rankings

Novo Nordisk is a global healthcare company headquartered in Denmark, that develops and manufactures pharmaceutical products, focusing mainly on diabetes and obesity care. The company was founded in 1923 and provides product access in 170 markets worldwide.

Courtesy of UCG via Getty

Fortune 100 Best Companies To Work For – Europe 2025

Novo Nordisk ranks 18 on this year’s Fortune 100 Best Companies to Work For – Europe list.

Read the Great Place To Work Review

Courtesy of Novo Nordisk

Fortune 100 Best Companies To Work For – Europe 2024

Danish healthcare company Novo Nordisk is on a mission to defeat chronic diseases—but it takes impact seriously in other areas, too. A Triple Bottom Line principle enshrined in the company’s Articles of Association ensures that business decisions balance financial, social and environmental considerations, and it is the first pharmaceutical company to use 100% renewable power in all its global production facilities. Internships, apprenticeships, graduate and accelerator schemes provide career entry points for students ranging from high school to postdoctoral, while workplace flexibility is shaped around job requirements and employee preferences, as well as local regulations, cultures and norms.

Read the Great Place To Work Review

Change the World 2026

The pharmaceutical company focuses on treating chronic diseases at massive scale, including diabetes and obesity. Like Eli Lilly, Novo Nordisk is striking back against copycat sellers of GLP-1 medications and compounders who make unproven claims about their medicines. Novo Nordisk also offers a reduced-price self-pay option for Ozempic and Wegovy to make the drugs more accessible and thus compete with unapproved compounded versions.

Updated:9/23/26
Country/Territory:Denmark
Headquarters:Bagsværd, Denmark
Industry:Pharmaceuticals
CEO:Maziar Mike Doustdar
Website:https://www.novonordisk.com

Ticker:NVO
Company type:Public
Revenues ($M):$46,711
Profits ($M):$15,482
Market value ($M):$202,907
Number of employees:69,505

Figures prepared in accordance with International Accounting Standards. Market value as of Aug. 31, 2026.

100% health coverage:No
Unlimited sick days:No
Telecommuting:Yes
Job sharing:Yes
Subsidized childcare:Yes
Compressed work weeks:Yes
Fully-paid sabbaticals:No
On-site fitness/subsidized gym:No

On-site medical care facility:No
Non-discrimination policy includes sexual orientation:Yes
Health insurance for part-timers:Yes
Sick days for part-timers:Yes
College tuition reimbursement:Yes
Student loan debt repayment:No
Medical facility at all locations:No

PTO limit (days):29
# Sick days:10

Most common job (for salaried employee):Sr. Diabetes Care Specialist
Avg. base pay (salaried):$107,300
Avg. extra compensation (salaried):$32,300
Total pay for most common job (salaried):$139,600

# of job applicants:19,219
Avg. # of applicants per opening:18
# New graduates hired:8

# of millennial employees:802
Millennials as % of total workforce:18%

% of Women in the Company:57%
% of Women in Executive/Manager Positions:43%

Sector:Natural resources
Industry:Pharmaceuticals
Current All-Star Rank:46
Previous All-Star Rank:-
Industry Rank:2
Previous Industry Rank:4
Overall Score:7.63
Innovation:2

People Management:4
Use of Corporate Assets:3
Social Responsibility:1
Quality of Management:2
Financial Soundness:3
Long-Term Investment Value:2
Quality of Products/Services:2
Global Competitiveness:3

Sector:Health Care
CEO/Top executive:Maziar Doustdar
Group headquarters:Denmark
HQ location:Denmark
GPTW national list:Austria, France, Ireland, Poland, Portugal, Turkey
Woman CEO:no
Number of Years on List:2

Sector:Health Care
Country:Denmark
Strongest dimension:Process innovation
Years on list:2
Previous rank:7

$ Millions% change
Revenues ($M):$46,71110.92%
Profits ($M):$15,4825.72%
Assets ($M):$85,369-
Total Stockholder Equity ($M):$30,513-

Profit as % of Revenues:33.1%
Profits as % of Assets:18.1%
Profits as % of Stockholder Equity:50.7%

Impact Segment:Public Health and Safety
Sector:Health Care

Novo Nordisk stock chart

Latest news on Novo Nordisk

Bank of America is splashing out $250 million a year on weight loss drugs for its staff: ‘We see a great impact on employees,’ CEO says

Weight-loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

Novo Nordisk in Fortune Rankings

View the Full List

Novo Nordisk

Novo Nordisk in Fortune Rankings

Novo Nordisk stock chart

Latest news on Novo Nordisk

Bank of America is splashing out $250 million a year on weight loss drugs for its staff: ‘We see a great impact on employees,’ CEO says

Weight-loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial

Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic

From retail to tech, here are the 10 corporations that recently announced mass layoffs

Novo Nordisk in Fortune Rankings

Videos